DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules
D5086C00001
Phase 3 small_molecule active
Quick answer
DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules for MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active